Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland

Osteoporosis International

Volumn 18, Issue 11, 2007, Pages 1481-1491

  Schwenkglenks, M ^a   Lippuner, K ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Alendronate; Bone densitometry; Cost utility analysis; Modelling studies; Osteoporosis; Switzerland

Indexed keywords

ALENDRONIC ACID;

ADULT; ARTICLE; BONE DENSITOMETRY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; SCREENING; SWITZERLAND;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; SEX FACTORS; SWITZERLAND;

EID: 34848841220     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0390-4     Document Type: Article

References (66)

1. (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650
2. Seeley DG, Browner WS, Nevitt MC et al (1991) Which fractures are associated with low appendicular bone mass in elderly women? The study of osteoporotic fractures research group. Ann Intern Med 115:837-842
3. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
4. Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16(Suppl 2):S8-S17
5. Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3-S7
6. Pasco JA, Sanders KM, Hoekstra FM et al (2005) The human cost of fracture. Osteoporos Int 16:2046-2052
7. Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139-1141
8. Nydegger V, Rizzoli R, Rapin CH et al (1991) Epidemiology of fractures of the proximal femur in Geneva: incidence, clinical and social aspects. Osteoporos Int 2:42-47
9. Johnell O, Kanis JA, Oden A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38-42
10. Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447-455
11. (2001) NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
12. Schwenkglenks M, Lippuner K, Hauselmann HJ et al (2005) A model of osteoporosis impact in Switzerland 2000-2020. Osteoporos Int 16:659-671
13. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535-1541
14. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group. J Clin Endocrinol Metab 85:4118-4124
15. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
16. Papapoulos SE, Quandt SA, Liberman UA et al (2005) Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468-474
17. Cranney A, Wells G, Willan A et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516
18. Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
19. Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252-5255
20. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
21. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299
22. Borgstrom F, Johnell O, Jonsson B et al (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064-1071
23. Christensen PM, Brixen K, Gyrd-Hansen D et al (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96:387-396
24. Goeree R, Blackhouse G, Adachi J (2006) Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 22:1425-1436
25. Johnell O, Jonsson B, Jonsson L et al (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305-314
26. Liu H, Michaud K, Nayak S et al (2006) The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166:1209-1217
27. Schousboe JT, Ensrud KE, Nyman JA et al (2005) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 53:1697-1704
28. Stevenson M, Lloyd Jones M, De Nigris E et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9(22)
29. Schousboe JT, Nyman JA, Kane RL et al (2005) Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142:734-741
30. Solomon DH, Kuntz KM (2000) Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum 43:1967-1975
31. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936
32. Organisation for Economic Co-operation and Development (OECD) (2007) Purchasing Power Parities (PPP). http://www.oecd.org/department/0,2688, en_2649_34357_1_1_1_1_1,00.html
33. Ubel PA, Hirth RA, Chernew ME et al (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163:1637-1641
34. Devlin N, Parkin D (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13:437-452
35. Looker AC, Johnston CC Jr, Wahner HW et al (1995) Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 10:796-802
36. Looker AC, Orwoll ES, Johnston CC Jr et al (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761-1768
37. Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195-202
38. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382
39. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
40. Chevalley T, Herman FR, Delmi M et al (2002) Evaluation of the age-adjusted incidence of hip fractures between urban and rural areas: the difference is not related to the prevalence of institutions for the elderly. Osteoporos Int 13:113-118
41. Schürch MA, Rizzoli R, Mermillod B et al (1996) A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 11:1935-1942
42. Chandler JM, Zimmerman SI, Girman CJ et al (2000) Low bone mineral density and risk of fracture in white female nursing home residents [see comments]. JAMA 284:972-977
43. Sugarman JR, Connell FA, Hansen A et al (2002) Hip fracture incidence in nursing home residents and community-dwelling older people, Washington State, 1993-1995. J Am Geriatr Soc 50:1638-1643
44. Cooper C, Atkinson EJ, O'Fallon WM et al (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227
45. Graafmans WC, Ooms ME, Bezemer PD et al (1996) Different risk profiles for hip fractures and distal forearm fractures: a prospective study. Osteoporos Int 6:427-431
46. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 344:333-340
47. Levis S, Quandt SA, Thompson D et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409-415
48. Tosteson AN, Jonsson B, Grima DT et al (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849-857
49. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123
50. Kanis JA, Oden A, Johnell O et al (2003) The components of excess mortality after hip fracture. Bone 32:468-473
51. Melton LJ 3rd (2000) Excess mortality following vertebral fracture. J Am Geriatr Soc 48:338-339
52. Pedersen K, Wittrup-Jensen K, Brooks R et al (2003) Værdisæ tning af sundhed-teorien om kvalitetsjusterede leveår og en dansk anvendelse. Syddansk Universitetsforlag, Odense
53. Kanis JA, Johnell O, Oden A et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26
54. Tosteson AN (2001) Impact of hip and vertebral fractures on quality adjusted life years. Osteoporos Int 12:1042-1049
55. Bonjour JP, Burckhardt P, Dambacher M et al (1997) Epidemiology of osteoporosis. Schweiz Med Wochenschr 127:659-667
56. Trombetti A, Herrmann F, Hoffmeyer P et al (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13:731-737
57. Szucs TD, Häuselmann HJ (2000) Die Wirtschaftlichkeit von Alendronat in der Behandlung der postmenopausalen Osteoporose. Gesundh Ökon Qual Manag 5:99-106
58. Hooven F, Gehlbach SH, Pekow P et al (2005) Follow-up treatment for osteoporosis after fracture. Osteoporos Int 16:296-301
59. Gasser KM, Mueller C, Zwahlen M et al (2005) Osteoporosis case finding in the general practice: phalangeal radiographic absorptiometry with and without risk factors for osteoporosis to select postmenopausal women eligible for lumbar spine and hip densitometry. Osteoporos Int 16:1353-1362
60. Abrahamsen B, Vestergaard P, Rud B et al (2006) Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish osteoporosis prevention study. J Bone Miner Res 21:796-800
61. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194
62. Kanis JA, Johnell O, Oden A et al (2005) Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography. Osteoporos Int 16:1065-1070
63. Kanis JA, Johnell O, Oden A et al (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995
64. Kanis JA, Johnell O, Oden A et al (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251-258
65. Eichler HG, Kong SX, Gerth WC et al (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518-528
66. Swiss Federal Office of Public Health (2007) Änderungen im Handbuch betreffend die Spezialitätenliste (SL) 2007. Swiss Federal Office of Public Health, Bern